tiprankstipranks
Advertisement
Advertisement
EDIT Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsEDIT Upcoming Earnings Report: What to Expect?
2M ago
Editas Medicine price target lowered to $3.50 from $12 at Chardan
Premium
The Fly
Editas Medicine price target lowered to $3.50 from $12 at Chardan
5M ago
FDA appoints Richard Pazdur as Director of CDER
Premium
The Fly
FDA appoints Richard Pazdur as Director of CDER
5M ago
Editas Medicine Inc. (EDIT) Q3 Earnings Cheat Sheet
PremiumPre-EarningsEditas Medicine Inc. (EDIT) Q3 Earnings Cheat Sheet
5M ago
FDA to speed up gene editing therapy approvals, Bloomberg reports
Premium
The Fly
FDA to speed up gene editing therapy approvals, Bloomberg reports
5M ago
Video: This stock is dragging down the in vivo gene editing therapy space
Premium
The Fly
Video: This stock is dragging down the in vivo gene editing therapy space
5M ago
Editas Medicine Unveils Promising Preclinical Data on EDIT-401
PremiumCompany AnnouncementsEditas Medicine Unveils Promising Preclinical Data on EDIT-401
6M ago
Editas Medicine reports in vivo preclinical PoC data for EDIT-401
Premium
The Fly
Editas Medicine reports in vivo preclinical PoC data for EDIT-401
6M ago
KalVista appoints Bilal Arif as COO, Linea Aspesi as CPO
Premium
The Fly
KalVista appoints Bilal Arif as COO, Linea Aspesi as CPO
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100